Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III and bioequivalence study of leuprolide acetate injectable suspension versus Eligard in Chinese patients with prostate cancer
CTR20262406Phase 3Active
- Sponsor
- Shanwan Biotech
- Start
- Jul 2026
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label trial of leuprolide in prostate cancer (PCa) (2 arms), sponsored by Shanwan Biotech. Primary endpoints: Cmax after first dose, AUC7-28d after first dose and 2 more. Started Jul 2026; status: active.
02
Drugs
leuprolide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20262406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262406.